Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 6/20 | 0.45 |
| ▸ | TDO2 | P48775 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232182 | 0.86 | EPHX1 (0.49) | METAP2METAP1IDO1TDO2CYP1A2 | |
| SCHEMBL10021099 | 0.83 | KMT2A (0.43) | METAP2METAP1MEN1KMT2ANPC1 | |
| SCHEMBL18660426 | 0.82 | NFE2L2 (0.44) | IDO1TDO2CYP1A2CYP2D6HIF1A | |
| SCHEMBL13275902 | 0.82 | IDO1 (0.45) | KMT2AIDO1TDO2CYP1A2CYP2D6 | |
| SCHEMBL10633563 | 0.82 | SLC6A2 (0.54) | METAP2IDO1TDO2NPC1RAB9A | |
| SCHEMBL1520497 | 0.81 | CYP1A2 (0.57) | METAP2METAP1IDO1TDO2CYP1A2 | |
| SCHEMBL7496186 | 0.79 | CYP1A2 (0.59) | CYP1A2CYP2D6HIF1A | |
| SCHEMBL1963900 | 0.79 | CYP1A2 (0.41) | IDO1TDO2CYP1A2CYP2D6HIF1A | |
| SCHEMBL2194901 | 0.79 | IDO1 (0.46) | IDO1TDO2 | |
| SCHEMBL22868100 | 0.79 | METAP2 (0.47) | METAP2METAP1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8278347-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8263593-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-7482475-B2 | Therapeutic lactams | ALLERGAN, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7439372-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2008100809-A1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | OLD DAVID W | 2008-03-06 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | METAP2 2001/4885METAP1 1498/4885MEN1 2538/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | METAP2 1932/4885METAP1 2699/4885MEN1 3829/4885 |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | METAP2 2001/4885METAP1 1498/4885MEN1 2538/4885 |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | METAP2 1561/4885METAP1 2339/4885MEN1 3123/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | METAP2 2630/4885METAP1 2587/4885MEN1 3331/4885 |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | METAP2 740/4885METAP1 1243/4885MEN1 3994/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | METAP2 1561/4885METAP1 2339/4885MEN1 3123/4885 |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | METAP2 1828/4885METAP1 2311/4885MEN1 4299/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | METAP2 480/4885METAP1 770/4885MEN1 1873/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | METAP2 1932/4885METAP1 2699/4885MEN1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.